Krsnaa Diagnostics Ltd (KRSNAA) — shareholding pattern, promoter holding, financials and share price

About Krsnaa Diagnostics Ltd (KRSNAA)

Krsnaa Diagnostics Ltd operates in the Healthcare Service Provider industry, within the Healthcare sector. It trades on the NSE as KRSNAA and on the BSE under scrip code 543328. Its ISIN is INE08LI01020.

Krsnaa Diagnostics Ltd provides a range of technology-enabled diagnostic services such as imaging, clinical laboratory, and teleradiology services to hospitals, medical colleges, and community health centers across India with an extensive network across non-metro and lower-tier cities and towns. [1]

Krsnaa Diagnostics is an integrated diagnostics provider operating radiology, pathology and teleradiology networks across India under PPP and retail models; the company reports roughly 190 CT/MRI centres, ~140 pathology labs, 4,000+ patient collection centres and has served more than 81 million patients since inception, with presence across 18 states and union territories.

Krsnaa’s model is radiology-led and PPP-focused, offering services at prices typically 50–70% below market while maintaining EBITDA and PAT positivity; this unusual combination signals a high-efficiency operating model that leverages scale, accreditation and low customer acquisition costs to serve underserved geographies profitably.

Listed peers in Healthcare Service Provider: Suraksha Diagnostic Ltd, One Global Service Provider Ltd, Health X Platform Ltd, 3B Blackbio DX Ltd, Gaudium IVF and Women Health Ltd, Chandan Healthcare Ltd.

Valuation & Returns

10 Jul 2026

At ₹552.55 a share on 10 Jul 2026, Krsnaa Diagnostics Ltd (KRSNAA) was valued at a price-to-earnings ratio of 17.67x against an industry P/E of 61.73x and a price-to-book of 2.03x on a book value of ₹272.14 per share as of Mar 2025. Solomo computes return on equity of 11.49% and return on capital employed of 15.16% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.

P/E
17.67x
Industry P/E
61.73x
P/B
2.03x
EPS (TTM)
₹31.27
Book value / share
₹272.14
ROE
11.49%
ROCE
15.16%
ROA
7.92%
Debt / equity
0.23x
Dividend yield
0.5%
EBITDA margin
33.02%
52-week range
₹502.2 – ₹891.8

Ratios are computed from filed results and the last recorded price. Not investment advice.

Financial Performance

Mar 2026

In the year ended Mar 2026, Krsnaa Diagnostics Ltd (KRSNAA) reported revenue of ₹773 crore, net profit of ₹101 crore and earnings per share of ₹31.27. That compares with revenue of ₹717 crore and net profit of ₹78 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.

In the quarter ended Mar 2026, revenue was ₹193 crore and net profit ₹42 crore (consolidated).

Consolidated annual results for Krsnaa Diagnostics Ltd (KRSNAA), Mar 2022 to Mar 2026. Revenue and net profit in ₹ crore; EPS in ₹ per share.
MetricMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue (₹ cr)455487620717773
Net profit (₹ cr)68625778101
EPS (₹)21.7819.7817.624.0431.27
Compound annual growth for Krsnaa Diagnostics Ltd (KRSNAA). Stock price CAGR is price return and excludes dividends.
Measure5Y3Y1Y
Sales growth21.41%14.44%15.76%
Profit growth-5.41%36.54%
Stock price CAGR-0%-34%

Ownership Summary

Jun 2026

As of Jun 2026, promoters hold 27.11% of Krsnaa Diagnostics Ltd (KRSNAA) (unchanged from the previous quarter), foreign institutional investors (FII) hold 4.28% and domestic institutional investors (DII) hold 14.51%. Market capitalisation was ₹1,792 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2021.

Largest disclosed public shareholders in Jun 2026: PHI CAPITAL TRUST - PHI CAPITAL GROWTH FUND - I 15.37%, TATA MUTUAL FUND - TATA SMALL CAP FUND 8.04%, AMICORP CAPITAL (MAURITIUS) LIMITED 2.18%, HDFC LIFE INSURANCE COMPANY LIMITED 2.05%, BANDHAN SMALL CAP FUND 1.98%, HUF 1.1%. Only stakes above the 1% disclosure threshold are named in filings.

QuarterPromoterPledgedFIIDIIPublic
Jun 202627.11%-4.28%14.51%72.89%
Mar 202627.11%-3.91%13.89%72.89%
Dec 202527.11%-4.17%13.86%72.89%
Sep 202527.11%-3.67%14.96%72.89%
Jun 202527.11%-3.4%14.24%72.89%
Mar 202527.24%-3.55%14.26%72.76%
Dec 202427.24%-4.04%14.46%72.76%
Sep 202427.17%-3.63%15.86%72.83%
Every quarter since Sep 2021 Filing data, not investment advice.